Viking Therapeutics (VKTX) said Tuesday it has signed a deal with CordenPharma to manufacture and supply both the active pharmaceutical ingredient and finished product for Viking's VK2735 program for obesity.
Under the terms of the deal, Viking said it will pay $150 million between 2025 and 2028 to CordenPharma, which has committed to provide an annual supply of over 1 billion oral tablets of VK2735 as well as 100 million autoinjectors and 100 million vial and syringe products for the subcutaneous formulation of VK2735.
Viking said it retains ownership of all global rights to VK2735, its investigational dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for metabolic disorders like obesity.
The company said it is conducting a phase 2 oral dosing trial of VK2735 and expects to begin a phase 3 study for the subcutaneous formulation in Q2.
Viking's stock was down 2% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。